Front Immunol (2018) 9:973
Disclosures: Henriette Kreimeyer: Nothing to Disclose, Carlos Gonzalez: Nothing to Disclose, Marcos Fondevila: Nothing to Disclose, Cynthia Hsu: Nothing to Disclose, Phillipp Hartmann: Nothing to Disclose, Xinlian Zhang: Nothing to Disclose, Peter Starkel: Nothing to Disclose, Francisco Bosques: Nothing to Disclose, Elizabeth Verna: Nothing to Disclose, Juan Abraldes: Gilead: Grant/Research Support, 89bio: Consultant, Boston Pharmaceuticals: Consultant, Novo Nordisk: Consultant, Boehringer Ingelheim: Consultant, Astra Zeneca: Consultant, Agomab: Consultant, Terumo: Speaking and Teaching, Cook: Grant/Research Support, Robert Brown: Gilead: Consultant, Intercept: Consultant, Abbvie: Consultant, Madrigal: Consultant, GSK: Consultant, eGenesis: Consultant, mirum: Consultant, Victor Vargas: Ipsen: Advisor, Orphalan: Speaking and Teaching, Jose Altamirano: Nothing to Disclose, Juan Caballeria: Nothing to Disclose, Debbie Shawcross: EnteroBiotix: Consultant, MRM Health: Advisor, Satellite Bio: Consultant, Norgine: Grant/Research Support, Apollo Therapeutics: Consultant, Genfit: Advisor, Alexandre LOUVET: Glaxo-Smith-Kline: Consultant, AbbVie: Speaking and Teaching, Gilead: Speaking and Teaching, Ipsen: Consultant, Astra-Zeneca: Speaking and Teaching, Michael Lucey: Nothing to Disclose, Philippe Mathurin: Nothing to Disclose, Guadalupe Garcia-Tsao: Nothing to Disclose, Ramon Bataller: Nothing to Disclose, Susan Mayo: Nothing to Disclose, David Gonzalez: Nothing to Disclose, Bernd Schnabl: Mabwell Therapeutics: Consultant, Ambys Medicines: Consultant, Surrozen: Consultant, Nterica Bio: Stock privately held company, Axial Biotherapeutics: Grant/Research Support, Prodigy Biotech: Grant/Research Support, CymaBay Therapeutics: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, ChromoLogic: Grant/Research Support 2069 NADH-REDUCTIVE STRESS LINKS THE ANTIOXIDANT CULLIN3-RING E3 LIGASE-NRF2 AXIS TO REGULATION OF HEPATIC STEATOSIS AND INSULIN SENSITIVITY Lijie Gu 1 Yanhong Du 1 Jianglei Chen 1 Mohammad Nazmul Hasan 1 Tiangang Li 1 , 1 University of Oklahoma Health Sciences Center Background Obesity and insulin resistance are major pathogenic drivers of metabolic dysfunction-associated steatotic liver disease (MASLD)
EFSA J 21
Refreshing fragrance with smooth foaming action
